656 related articles for article (PubMed ID: 24965257)
1. Myeloid-derived suppressor cell heterogeneity in human cancers.
Solito S; Marigo I; Pinton L; Damuzzo V; Mandruzzato S; Bronte V
Ann N Y Acad Sci; 2014 Jun; 1319():47-65. PubMed ID: 24965257
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
3. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
Khaled YS; Ammori BJ; Elkord E
Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
[TBL] [Abstract][Full Text] [Related]
5. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
Fujimura T; Mahnke K; Enk AH
J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
7. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of myeloid-derived suppressor cells.
Ugel S; Delpozzo F; Desantis G; Papalini F; Simonato F; Sonda N; Zilio S; Bronte V
Curr Opin Pharmacol; 2009 Aug; 9(4):470-81. PubMed ID: 19616475
[TBL] [Abstract][Full Text] [Related]
9. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells.
Tian J; Ma J; Ma K; Guo H; Baidoo SE; Zhang Y; Yan J; Lu L; Xu H; Wang S
Eur J Immunol; 2013 May; 43(5):1220-30. PubMed ID: 23424024
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
[TBL] [Abstract][Full Text] [Related]
11. Myeloid cell population dynamics in healthy and tumor-bearing mice.
Ueha S; Shand FH; Matsushima K
Int Immunopharmacol; 2011 Jul; 11(7):783-8. PubMed ID: 21406269
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
13. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients.
Jiang J; Guo W; Liang X
Hum Immunol; 2014 Nov; 75(11):1128-37. PubMed ID: 25305034
[TBL] [Abstract][Full Text] [Related]
14. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer.
Ohki S; Shibata M; Gonda K; Machida T; Shimura T; Nakamura I; Ohtake T; Koyama Y; Suzuki S; Ohto H; Takenoshita S
Oncol Rep; 2012 Aug; 28(2):453-8. PubMed ID: 22614133
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
Montero AJ; Diaz-Montero CM; Kyriakopoulos CE; Bronte V; Mandruzzato S
J Immunother; 2012; 35(2):107-15. PubMed ID: 22306898
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
[TBL] [Abstract][Full Text] [Related]
18. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects of myeloid-derived suppressor cells in diseases: Role in cancer and infections.
Tamadaho RSE; Hoerauf A; Layland LE
Immunobiology; 2018; 223(4-5):432-442. PubMed ID: 29246400
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers.
Lim HX; Kim TS; Poh CL
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
